Role of ablation therapy in conjunction with surgical resection for neuroendocrine tumors involving the liver

Table 2 Outcomes of patients treated for metastatic neuroendocrine tumors to the liver (n = 966), n (%)

Outcome	Surgical treatment only, n = 668 (69.2%)	Surgery + ablation treatment, n = 298 (30.8%)	P value
Death	7 (1.1)	3 (1.0)	1.00
Significant bleed	117 (17.5)	33 (11.1)	0.0111
Bile leak	41 (6.2)	14 (4.8)	0.38
Myocardial infarction	3 (0.5)	1 (0.3)	1.00
Pulmonary embolism	11 (1.7)	4 (1.3)	1.00
Pneumonia	17 (2.5)	8 (2.7)	0.90
Sepsis	21 (3.1)	16 (5.4)	0.096
Liver failure	23 (3.4)	4 (1.3)	0.089
Return to operating room	24 (3.6)	7 (2.4)	0.31
Readmission	73 (10.9)	34 (11.4)	0.83
Surgical site infection
Superficial	27 (4.0)	10 (3.4)	0.61
Deep incisional	4 (0.6)	1 (0.3)	1.00
Organ space	48 (7.2)	30 (10.1)	0.13
Wound	4 (0.6)	1 (0.3)	1.00
Any	78 (11.7)	39 (13.1)	0.54

¹Indicates significance at P < 0.05 level.